目的探讨复方苦参注射液治疗Ⅲ-Ⅳ期癌症患者癌性疼痛的临床效果。方法 2010年1月至2014年1月山东省胸科医院肿瘤内科收治的122例恶性肿瘤患者,随机分为治疗组和对照组,每组61例。对照组采用常规治疗,治疗组在常规治疗的基础上加用复方...目的探讨复方苦参注射液治疗Ⅲ-Ⅳ期癌症患者癌性疼痛的临床效果。方法 2010年1月至2014年1月山东省胸科医院肿瘤内科收治的122例恶性肿瘤患者,随机分为治疗组和对照组,每组61例。对照组采用常规治疗,治疗组在常规治疗的基础上加用复方苦参注射液25 m L溶于250 m L生理盐水中静滴,1次/d,两周为1个疗程。对两组患者治疗后的疼痛评分、疼痛缓解的有效率及不良反应情况进行评价。结果治疗后治疗组患者疼痛评分降低显著,两组间差异具有统计学意义（P〈0.05）;治疗组和对照组患者疼痛缓解的有效率分别为81.97%和52.45%,差异具有统计学意义（P〈0.05）。结论复方苦参注射液可有效缓解Ⅲ~Ⅳ期癌症患者癌性疼痛,无明显不良反应,值得深入研究。展开更多
Locally advanced pancreatic cancer is associated with a very poor prognosis. This study was performed to evaluate whether patients with locally advanced pancreatic cancer benefit from 125 ^I seed implantation. This re...Locally advanced pancreatic cancer is associated with a very poor prognosis. This study was performed to evaluate whether patients with locally advanced pancreatic cancer benefit from 125 ^I seed implantation. This retrospective study included 224 patients with locally advanced pancreatic cancer, with 137 patients（61.2%） in the implantation（IP） group and 87（38.9%） in the non-implantation（NIP） group. The survival status, complications and objective curative effects were compared between the groups. The average operative time in the IP group was significantly longer than that in the NIP group（243±51 vs. 214±77 min）. The tumor response rates were 9.5% and 0 at the 2nd month after surgery in the IP and NIP groups, respectively（P〈0.05）. The IP group exhibited a trend toward pain relief at the 6th month after surgery. The global health status scores of the IP group were higher than those of the NIP group at the 3rd and 6th month after surgery. The median survival time in the IP group was significantly longer than that in the NIP group. In conclusion, patients with locally advanced pancreatic cancer can benefit from 125 I seed implantation in terms of local tumor control, survival time, pain relief and quality of life.展开更多
文摘目的探讨复方苦参注射液治疗Ⅲ-Ⅳ期癌症患者癌性疼痛的临床效果。方法 2010年1月至2014年1月山东省胸科医院肿瘤内科收治的122例恶性肿瘤患者,随机分为治疗组和对照组,每组61例。对照组采用常规治疗,治疗组在常规治疗的基础上加用复方苦参注射液25 m L溶于250 m L生理盐水中静滴,1次/d,两周为1个疗程。对两组患者治疗后的疼痛评分、疼痛缓解的有效率及不良反应情况进行评价。结果治疗后治疗组患者疼痛评分降低显著,两组间差异具有统计学意义（P〈0.05）;治疗组和对照组患者疼痛缓解的有效率分别为81.97%和52.45%,差异具有统计学意义（P〈0.05）。结论复方苦参注射液可有效缓解Ⅲ~Ⅳ期癌症患者癌性疼痛,无明显不良反应,值得深入研究。
文摘Locally advanced pancreatic cancer is associated with a very poor prognosis. This study was performed to evaluate whether patients with locally advanced pancreatic cancer benefit from 125 ^I seed implantation. This retrospective study included 224 patients with locally advanced pancreatic cancer, with 137 patients（61.2%） in the implantation（IP） group and 87（38.9%） in the non-implantation（NIP） group. The survival status, complications and objective curative effects were compared between the groups. The average operative time in the IP group was significantly longer than that in the NIP group（243±51 vs. 214±77 min）. The tumor response rates were 9.5% and 0 at the 2nd month after surgery in the IP and NIP groups, respectively（P〈0.05）. The IP group exhibited a trend toward pain relief at the 6th month after surgery. The global health status scores of the IP group were higher than those of the NIP group at the 3rd and 6th month after surgery. The median survival time in the IP group was significantly longer than that in the NIP group. In conclusion, patients with locally advanced pancreatic cancer can benefit from 125 I seed implantation in terms of local tumor control, survival time, pain relief and quality of life.
